Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) is a biotechnology company in the clinical stage. It aims to improve the efficacy of current standard-of-care treatments, such as radiation therapy and chemotherapy, to increase the life expectancy of cancer patients.

Key Highlights:

• The company has yet to record revenue from operations, and it does not anticipate generating revenue from product sales shortly.
• The net loss in Q3FY21 jumped to USD 12.20 billion from USD 4.44 billion in Q3FY20, owing to a USD 8.64 billion impairment charge on in-process research and development.
• The company is constantly issuing its common stock and warrants, which dilutes existing shareholders' holdings and diminishes their ownership in the company.
• Stock is currently trading below its crucial short-term as well as long-term 50-day and 200-day SMA support levels, a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 0.22 to USD 1.85.
• DFFN's share price has declined 56.12% and 67.83% in the past six and nine months, respectively.

Technical Price Chart (as of January 28, 2022). Analysis by Kalkine

Conclusion: The company has not reported any revenues to date. Given the unstable fundamentals, lack of clarity in top-line growth, and bleak outlook, we recommend an "Avoid" rating on the stock at the closing price of USD 0.2414, down 0.45%, as of January 28, 2022.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.